Veterinary Anti-infectives Market Size, Share, Growth, Trends, and Global Industry Analysis: By Drug Type (Anti-viral Drugs, Anti-bacterial Drugs, Parasiticides, Anti-fungal Drugs, Others), By Disease Type (Dermatological infections, Respiratory infections, Gastrointestinal Infections, Ophthalmic Infections, Others), By Species Type (Farm Animals (Cattle, Aqua, Swine, Sheep, Poultry, Others), Companion Animals (Canines, Felines, Horses, Rabbits, Others)), By Route Of Administration (Oral, Parenteral, Topical, Others), By Distribution Channel (Veterinary Hospitals, Veterinary Pharmacies, Online Pharmacies, Others) and Region

Veterinary Anti-infectives Market Size was valued at US$ 1.42 billion in 2023 and is poised to grow at a CAGR of 3.6% from 2024-2030. Veterinary anti-infectives are medications that work to prevent or treat infections in animals by inhibiting the spread of an infectious organism or by killing the infectious organism outright. Animals might acquire a number of infections that are transmitted by food, water, or even zoonotic diseases. According to the global animal health association, it’s estimated that one in five farm animals are lost due to diseases each year with 20% of animals lost to preventable diseases. The zoonotic diseases i.e., diseases spread from animals to humans like Rabies, Anthrax, Brucellosis, Foot and Mouth disease, and others. The veterinary anti-infectives market driving factors include increased awareness among the farmers coupled with the availability of novel therapeutics, favourable government policies. For example, in 2014, West Africa experienced the largest Ebola outbreak infecting 28,616 people and 11,310 deaths. Moreover, the pressure to maintain veterinary health standards of dairy products, fresh meat, and dietary nutrition creates pressure on livestock owners which is expected to hasten the use of veterinary anti-infectives. Furthermore, the increased adoption of pets has increased the veterinary anti-infectives market.

According to the American Society for the Prevention of Cruelty to Animals (ASPCA) more than 23 million American households adopted a pet in the pandemic duration. Improvisation in research and development, and product innovation in areas such as biologics and specialty care provide a huge array of opportunities for this market. Additionally, the veterinary anti-infectives market is expected to experience considerable development prospects, particularly for new market entrants, due to the rising affordability of therapies and rising consumer awareness of livestock and pet care. Based on drug type, the anti-bacterial segment has accounted for major revenue share. For instance, according to research conducted in Tanzania, Tanzania Medicines and Medical Devices Authority (TMDA) recorded, a total of 12,147,491 kg of antibiotics consumption from 2010 to 2017. But the presence of substandard or counterfeit drugs hinders the growth of the market. Moreover, the increased cost of veterinary services and lack of accessibility to vets along with the negligence of livestock owners with numerous animals towards the sick cattle is decreasing the value of the veterinary anti-infectives market. However, increased investments by major industry leaders in research and development, entry of generic medicines, developed infrastructure, increased demand for poultry food items, and increased rate of pet adoption are major facets in this market contributing towards its overall growth and are expected to increase the market in the forecast years.

Veterinary Anti-infectives Market Key Developments:

• In September 2022, Zoetis acquired Jurox, a leading animal health company that develops, manufactures, and markets a wide range of veterinary medicines for treating livestock and companion animals.
• In July 2022, Dechra Pharmaceuticals of Northwich, England acquired Greensboro-based Piedmont Animal Health, an innovator of more than 30 pet medicines sold by major global brands for $210 million.